Sage Therapeutics - SAGE Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings or view top-rated stocks.

12 brokers have issued 1 year price targets for Sage Therapeutics' shares. Their SAGE share price forecasts range from $37.00 to $73.00. On average, they anticipate the company's share price to reach $48.29 in the next twelve months. This suggests a possible upside of 7.4% from the stock's current price.
View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts.

Sage Therapeutics' stock was trading at $38.14 at the beginning of 2023. Since then, SAGE stock has increased by 17.9% and is now trading at $44.97.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our SAGE earnings forecast.

Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($2.31) EPS for the quarter, missing the consensus estimate of ($2.16) by $0.15. The biopharmaceutical company had revenue of $1.74 million for the quarter, compared to analyst estimates of $1.68 million. Sage Therapeutics had a negative net margin of 7,895.27% and a negative trailing twelve-month return on equity of 32.76%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Sage Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.30%), Baillie Gifford & Co. (0.16%), Allspring Global Investments Holdings LLC (0.15%), Hennion & Walsh Asset Management Inc. (0.12%), Pendal Group Ltd (0.01%) and Inspire Investing LLC (0.01%). Insiders that own company stock include Barry E Greene, Barry E Greene, George Golumbeski and James M Frates.
View institutional ownership trends.

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAGE stock can currently be purchased for approximately $44.97.

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.68 billion and generates $6.31 million in revenue each year. The biopharmaceutical company earns $-457,890,000.00 in net income (profit) each year or ($8.63) on an earnings per share basis.

The company employs 471 workers across the globe.

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.